Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 years. 2. Ischemic stroke. 3. History of spontaneous, non-traumatic deep intracerebral hemorrhage confirmed by CT or MRI, located in the basal ganglia, thalamus, pons, or deep cerebellum, with no lobar cortical involvement and no intraventricular hemorrhage. 4. Non-valvular atrial fibrillation, including paroxysmal, persistent, or permanent atrial fibrillation. 5. Written informed consent provided by the participant or a legally authorized representative. Exclusion Criteria: 1. Modified Rankin Scale (mRS) score \>3. 2. MRI evidence of cortical superficial siderosis (cSS) or severe lobar cerebral microbleeds. 3. Severe uncontrolled hypertension refractory to medical therapy. 4. Severe renal impairment with creatinine clearance (CrCl) \<30 mL/min. 5. Requirement for continuous oral anticoagulation for an indication other than atrial fibrillation, such as a mechanical heart valve or venous thromboembolism. 6. Requirement for continued antiplatelet therapy that cannot be replaced by oral anticoagulation. 7. Contraindication to apixaban according to the approved prescribing information, other than the history of spontaneous intracerebral hemorrhage, including hypersensitivity, active bleeding, other high-risk bleeding lesions, or hepatic disease associated with coagulopathy and clinically relevant bleeding risk. 8. Previous or planned left atrial appendage occlusion. 9. Pregnancy, breastfeeding, or planned pregnancy during the study period. 10. Inability to comply with study procedures or an expected life expectancy \<6 months.